Pharmafit Provence
BORAX/BORIC ACID VIATRIS 12 mg/18 mg/ml Solution for ophthalmic rinsing in single-dose container 20Single-dose/5ml

BORAX/BORIC ACID VIATRIS 12 mg/18 mg/ml Solution for ophthalmic rinsing in single-dose container 20Single-dose/5ml

VIDAL information
Your professional account

PharmaFit supplies pharmacies and healthcare professionals. Access your purchasing terms and availability through your professional account.

Access is reserved for authorised professionals, following account approval.

Contact PharmaFit

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of 24/01/2024

BORAX/BORIC ACID VIATRIS 12 mg/18 mg/mL, solution for ophthalmic washing in unit-dose container


Forms and presentations

Ophthalmic irrigation solution.


Composition

Borax...............................................................................................................................................................12 mg

Boric acid ................................................................................................................................................18 mg

For 1 mL of solution.


Excipients:

Sodium chloride, rose distilled water, purified water.



Indications

Eye irrigation in case of conjunctival irritation.



Dosage and administration

Dosage

For eye irrigation

1 to 3 eye irrigations per day.

Paediatric population

No data are available.

Method of administration

Topical use.

Irrigation is performed directly by jet, by turning the single-dose container upside down and gently pressing on it, taking care not to bring the single-dose container into contact with the surface of the eye, and wiping off the excess with a compress or absorbent cotton.

Use the single-dose container immediately after opening and discard it after use.

The single-dose container may be used for treating both eyes.

Do not reuse an opened single-dose container.

In case of concomitant treatment with eye drops, it is advisable to wait 15 minutes before instilling them.



Contraindications

Hypersensitivity to boric acid, borax or to any of the excipients listed in section Composition.



Warnings and precautions

Do not inject, do not swallow.

This product does not contain a preservative. This product may be used in patients wearing contact lenses; however, it is advised to remove them before performing eye irrigation. Due to the risk of rapid bacterial contamination, an opened single-dose container must never be reused for subsequent administrations.

Discard the single-dose container immediately after use.



Interactions

In case of concomitant treatment with an eye drop containing a different active ingredient, separate the instillations by 15 minutes.



Fertility, pregnancy and breastfeeding

Use with caution in pregnant or breastfeeding women, due to a lack of usable clinical data.



Driving and using machines

A transient visual disturbance may occur after instillation of the solution eye drops and may affect the ability to drive vehicles or use machines.

In this case, it is advised not to drive or use machines until normal vision returns.



Adverse effects

The adverse effects identified during clinical trials and after marketing with the association of borax/boric acid are listed by organ system in order of frequency in the table below according to the following convention:

Very common (≥1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1000, < 1/100); rare (≥ 1/10000, < 1/1000); very rare (< 1/10000); frequency not known (cannot be estimated from the available data).

System organ class

Frequency

Adverse reaction

Eye disorders

Rare

Eye irritation.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Centres of Pharmacovigilance - Website: https://signalement.social-sante.gouv.fr/.



Overdose

No cases of overdose have been reported.

In case of irritation, rinse with sterile physiological saline.



Pharmacodynamics

Pharmacotherapeutic class: LOCAL ANTISEPTIC/MILD ASTRINGENT FOR OPHTHALMIC USE. ATC code: (S: sensory organs).



Shelf life

3 years.



Special storage precautions

This medicine does not require any particular storage precautions.

After use, the single-dose container must be discarded.

Do not reuse a single-dose container that has already been opened.



SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

No special requirements.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400930190630 (10Unit/5ml).
CIP 3400930190647 (20Unit/5ml).
Price:
1,87 euros (20 Unit/5 ml).
Social Security reimbursement at 30% (20Unit/5ml) in the indications:
  • Indication(s) appearing in the marketing authorization at the publication date of this order (20Unit/5ml)

Not reimbursed by Social Security (10Unit/5ml).
Collection (20Unit/5ml).

Viatris Santé
1 RUE DE TURIN
69007 LYON
Tel: 04 37 25 75 00 https://www.viatris.fr/

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.